Structure

InChI Key DDTDNCYHLGRFBM-YZEKDTGTSA-N
Smile CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O
InChI
InChI=1S/C80H81Cl2N9O33/c1-26(95)84-59-65(104)62(101)50(23-92)120-78(59)123-69-31-6-10-45(40(82)16-31)118-49-19-33-18-48(70(49)124-79-60(85-27(2)96)66(105)63(102)51(24-93)121-79)117-44-9-3-28(11-39(44)81)12-41-71(108)87-56(32-13-34(97)20-36(14-32)116-46-17-29(4-8-43(46)100)54(83)72(109)86-41)74(111)89-57(33)75(112)88-55-30-5-7-42(99)37(15-30)53-38(58(77(114)115)90-76(113)61(69)91-73(55)110)21-35(98)22-47(53)119-80-68(107)67(106)64(103)52(25-94)122-80/h3-11,13-22,41,50-52,54-69,78-80,92-94,97-107H,12,23-25,83H2,1-2H3,(H,84,95)(H,85,96)(H,86,109)(H,87,108)(H,88,112)(H,89,111)(H,90,113)(H,91,110)(H,114,115)/t41-,50+,51+,52-,54-,55-,56+,57-,58+,59+,60+,61+,62-,63-,64-,65-,66-,67-,68+,69-,78+,79+,80+/m1/s1

Pharmacology

Action Mechanism of Action Reference
DISRUPTING AGENT Peptidoglycan disrupting agent PubMed EMA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Infections 3 D007239 ClinicalTrials
Skin Diseases 3 D012871 ClinicalTrials
Osteomyelitis 2 D010019 ClinicalTrials
Cystic Fibrosis 1 D003550 ClinicalTrials

Related Entries

Scaffolds

Cross References

Resources Reference
CAS NUMBER 61036-62-2
ChEMBL CHEMBL4297166
FDA SRS 4U3D3YY81M
Guide to Pharmacology 10924